NCT07627464Not yet recruitingPhase 2
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
A Multicenter, Randomized Controlled Phase II Study of Neoadjuvant Anlotinib Hydrochloride Capsules Combined With Benmelstobart Injection Versus Surgery Alone for Localized Renal Cell Carcinoma Planned for Partial Nephrectomy
Source: ClinicalTrials.gov · Last updated 4 Jun 2026
Brief summary (registry, in English)
Evaluation of long-term renal function improvement, surgical safety, as well as efficacy and safety of preoperative anlotinib hydrochloride capsules combined with benmelstobart injection versus surgery in patients with localized renal cell carcinoma undergoing partial nephrectomy
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- First submitted
- 20 May 2026
- Start date
- 31 May 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT07627464
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 144
- From 31 May 2026 to the primary completion date, 31 Dec 2028
- 14 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects with a prior history of renal transplantation.
Other illness
- Subjects with hereditary or familial renal tumors (e.g., von Hippel-Lindau \[VHL\] disease).
Other
- Subjects with a solitary kidney tumor.
- Subjects with bilateral renal tumors or unilateral multiple renal tumors (n ≥ 2).
Who the study is looking for
- Aged between 18 and 75 years, inclusive.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Subjects with newly diagnosed cT1bN0M0 renal cell carcinoma (RCC) scheduled to undergo partial nephrectomy.
- Have at least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- No prior systemic therapy for renal cell carcinoma, including but not limited to targeted therapy, immunotherapy, investigational therapy, or hormone therapy.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (14)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University Third Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Jilin Provincial Cancer Hospital Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
| Hunan Provincial Cancer Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| The First Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Yunnan Provincial Cancer Hospital Coordinator of this site? Confirm its status | Kunming | China | Unknown status |
| Nanjing Drum Tower hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| The First Affiliated Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
| The Affiliated Hospital of Qingdao University Coordinator of this site? Confirm its status | Qingdao | China | Unknown status |
| Huadong Hospital Affiliated to Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Liaoning Provincial Cancer Hospital Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
| Shanxi Province Cancer Hospital Coordinator of this site? Confirm its status | Taiyuan | China | Unknown status |
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
| The First Affiliated Hospital of Zhengzhou University Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.